Population pharmacokinetics and standard uptake value ratio of aducanumab, an amyloid plaque–removing agent, in patients with Alzheimer’s disease

Population pharmacokinetics and standard uptake value ratio of aducanumab, an amyloid plaque–removing agent, in patients with Alzheimer’s disease

Abstract Aducanumab is a human immunoglobulin G1 anti‐amyloid beta (Aβ) antibody currently being evaluated for potential treatment of patients with early Alzheimer’s disease. This paper describes the relationship between the population pharmacokinetics (PopPKs) and pharmacokinetics‐pharmacodynamics...

Full description

Bibliographic Details
Main Authors: Kumar Kandadi Muralidharan, Xiao Tong, Kenneth G. Kowalski, Raj Rajagovindan, Lin Lin, Samantha Budd Haberlain, Ivan Nestorov
Format: Article
Language:English
Published: Wiley 2022-01-01
Series:CPT: Pharmacometrics & Systems Pharmacology
Online Access:https://doi.org/10.1002/psp4.12728

Internet

https://doi.org/10.1002/psp4.12728

Similar Items